HistoSonics was named by The Observer as one of the nation’s most influential healthcare companies during the 38th J.P. Morgan Healthcare Investment Conference in San Francisco, CA.
The company’s platform, Edison, integrates imaging, and proprietary sensing technology, and uses the science of histotripsy and the mechanical properties of focused ultrasound to destroy and liquify targeted tissues at sub-cellular levels, while preserving non-target tissue, which The Observer likened to advanced technology from science fiction movies set years in the future. The Observer’s complete list of top “Flyover Tech” firms released recognizes leading digital health and medical technology start-ups residing in the US heartland and that are transforming their respective fields.
“We are honored to lead The Observer’s list of innovative healthcare companies,” said HistoSonics CEO and President Mike Blue. “We are equally proud to call Ann Arbor and Minneapolis home as we continue to expand our capabilities at each location.” The company recently completed its first clinical study in liver tumors, opened a new corporate headquarters, manufacturing and training center in Minnesota, and raised $54M in a Series C financing closed in 2019 which included heavyweight healthcare leaders Varian Medical Systems and Johnson & Johnson Innovation, JJDC, Inc., among others.
HistoSonics proprietary technology is designed to provide potentially significant advantages to patients, including the non-invasive destruction of tumors without the need for surgery or other invasive procedures, while also providing physicians the unique ability to monitor and control the destruction of target tissue under continuous real-time visualization, unlike any modality that exists today.
Edison is not yet commercially available. Final performance specifications are subject to change pending the completion of regulatory market-access activities.
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.
